While Keros Therapeutics Inc has overperformed by 0.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KROS fell by -80.14%, with highs and lows ranging from $73.00 to $9.77, whereas the simple moving average fell by -76.15% in the last 200 days.
On January 21, 2025, Cantor Fitzgerald Downgraded Keros Therapeutics Inc (NASDAQ: KROS) to Neutral. A report published by Wedbush on January 17, 2025, Downgraded its rating to ‘Neutral’ for KROS. Oppenheimer also reiterated KROS shares as ‘Outperform’, quoting a target price of $63 on the company’s shares in a report dated December 16, 2024. H.C. Wainwright resumed its ‘Buy’ rating for KROS, as published in its report on December 13, 2024. TD Cowen also rated the stock as ‘Hold’.
Analysis of Keros Therapeutics Inc (KROS)
Further, the quarter-over-quarter increase in sales is 4750.00%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Keros Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -43.82% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and KROS is recording an average volume of 1.44M. On a monthly basis, the volatility of the stock is set at 6.31%, whereas on a weekly basis, it is put at 5.10%, with a loss of -0.18% over the past seven days. Furthermore, long-term investors anticipate a median target price of $34.36, showing growth from the present price of $11.37, which can serve as yet another indication of whether KROS is worth investing in or should be passed over.
How Do You Analyze Keros Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 18.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 83.13% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
KROS shares are owned by institutional investors to the tune of 83.13% at present.
